U.S. stock futures rise after U.S.-Japan trade deal; Tesla, Alphabet earnings due
On Monday, Cerus Corporation (NASDAQ:CERS), a medical device company with a market capitalization of $273 million and a recent strong performance of +14% over the past week, announced the results of its recent Annual Meeting of Stockholders held on Sunday. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment, with analysts maintaining a Strong Buy consensus. The key agenda included the election of directors, approval of an amendment to the equity incentive plan, an advisory vote on executive compensation, and the ratification of the company’s independent registered public accounting firm.
The stockholders elected Jami Dover (NYSE:DOV) Nachtsheim and Hua Shan, MD, Ph.D., to the Board of Directors to serve until the 2028 Annual Meeting or until their successors are elected and qualified. Nachtsheim received 107,020,992 votes for, 7,011,149 withheld, and there were 44,116,421 broker non-votes. Shan secured 111,424,285 votes for, 2,607,856 withheld, alongside the same number of broker non-votes. The company maintains a healthy financial position with a current ratio of 2.32 and has demonstrated solid revenue growth of 13% in the last twelve months.
Additionally, the shareholders approved the amendment and restatement of the Company’s 2024 Equity Incentive Plan, with 74,344,720 votes for, 39,504,222 against, 183,199 abstentions, and 44,116,421 broker non-votes.
The advisory vote on the compensation of the company’s named executive officers as disclosed in the Proxy Statement also passed with 104,504,639 votes for, 9,321,156 against, and 206,346 abstentions. There were 44,116,421 broker non-votes on this proposal as well.
Finally, the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with a significant majority of 153,189,590 votes for, 4,332,938 against, and 626,034 abstentions.
No other matters were submitted for stockholder action at the Annual Meeting. The full details of the meeting outcomes are based on the company’s recent SEC filing. For deeper insights into Cerus Corporation’s financial health, growth prospects, and detailed analysis, investors can access comprehensive research reports and additional ProTips through InvestingPro’s extensive coverage of over 1,400 US stocks.
In other recent news, Cerus Corporation reported its Q1 2025 earnings, showing a net loss of $7.7 million or $0.04 per share, which aligned with analyst expectations. The company generated $48.9 million in revenue, slightly below the anticipated $49.61 million, despite a 13% year-over-year increase in product revenue. North American revenues surged by 22%, while the EMEA region saw a slight decline. Cerus also received regulatory approvals for its new INT200 blood safety device in France and Switzerland, enhancing operations for their INTERCEPT Blood System. Cantor Fitzgerald maintained an Overweight rating on Cerus, reflecting confidence in the company’s growth prospects in the platelet market. Additionally, Cerus is set to present new data on its INTERCEPT Blood System at the ISBT Congress, highlighting its efficacy in various blood components. The company plans further regulatory submissions, including a premarket approval to the FDA in 2026 for the INT200 device. These developments underscore Cerus’ ongoing efforts to enhance blood safety and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.